Email
Password
Remember meForgot password?
    Log in with Twitter
| Press Release

Blog Exposure - ArQule Signed License Agreement with Roivant Sciences to Develop Derazantinib In China

Stock Monitor: Regeneron Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 09, 2018 / Active-Investors.com has just released a free research report on ArQule, Inc. (NASDAQ: ARQL). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARQL as the Company's latest news hit the wire. On February 07, 2018, the Company announced that it has collaborated with Switzerland-based Roivant Sciences to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater China. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), which also belongs to the Healthcare sector as the Company ArQule. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=REGN

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, ArQule most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ARQL

Details of the Collaboration

As per the terms of the partnership, Roivant subsidiary has been granted an exclusive license to develop and commercialize derazantinib in the People's Republic of China, Hong Kong, Macau, and Taiwan. Roivant made an upfront payment to ArQule of approximately $3 million along with an additional $2.5 million development milestone payment within the first year. The latter is also eligible for regulatory and commercial milestones and royalties on future sales of derazantinib in Greater China.

Roivant Intends to Pursue Development of Derazantinib in China for Treatment of iCCA

ArQule is currently conducting a registrational trial for derazantinib in the United States and Europe as a potential treatment for intrahepatic cholangiocarcinoma (iCCA), a form of biliary tract cancer. The People's Republic of China has one of the world's highest incidences of iCCA, where it is the second most common form of liver cancer. Roivant intends to pursue the development of derazantinib in China for the treatment of iCCA while also pursuing further development in other tumor types with high rates of FGFR mutation.

ArQule Initiated Dosing in a Registrational Trial of Derazantinib for Treatment of iCCA

In November 2017, ArQule announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib in FGFR2 fusion driven second-line iCCA. The trial is planned to enroll up to 100 iCCA patients and provides an opportunity for a conditional approval as part of a fast-to-market strategy.

In June 2013, derazantinib demonstrated favorable clinical data in a biomarker-driven Phase-1/2 trial in iCCA targeting patients with FGFR2 fusions. The data show a robust response rate and prolonged duration of therapy for these patients well in excess of that reported for second-line chemotherapy. Both the FDA and EMA have granted ArQule orphan drug designation for this disease.

About Intrahepatic Cholangiocarcinoma

iCCA (bile duct cancer) is a rare and difficult to treat cancer that occurs in the small, tube-like bile ducts within the liver that carry bile to the gallbladder. Depending on the anatomic location, CCA is classified as intrahepatic (iCCA), perihilar (pCCA), and extrahepatic (eCCA). Current treatment is based on the patient's stage of the cancer when diagnosed and include resection, chemoradiation, and systemic chemotherapy.

About Derazantinib

Derazantinib (ARQ 087) is a potent, orally administered inhibitor of the FGFR family, a key driver of cell proliferation, differentiation, and migration. Derazantinib is designed to preferentially inhibit the FGFR family of kinases with demonstrated activity in FGFR2 genetic alterations, including fusions.

About ArQule, Inc.

Founded in 1993 and headquartered in Burlington, Massachusetts, ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. The Company's mission is to discover, develop, and commercialize novel small molecule drugs in areas of high unmet need.

About Roivant Sciences

Established in 2014, Roivant Sciences is a global healthcare company focused on realizing the full value of promising biomedical research to improve the lives of patients. The Company's mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the broader healthcare system. Roivant is based in Basel, Basel-Stadt.

Stock Performance Snapshot

February 08, 2018 - At Thursday's closing bell, ArQule's stock slightly rose 0.61%, ending the trading session at $1.66.

Volume traded for the day: 88.62 thousand shares.

Stock performance in the last three-month – up 62.75%; previous six-month period – up 66.00%; past twelve-month period – up 22.96%; and year-to-date - up 0.61%

After yesterday's close, ArQule's market cap was at $143.71 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors